Replay available

Mirum Pharmaceuticals (NASDAQ:MIRM) Q2 2021 Earnings Call

Mirum Pharmaceuticals (NASDAQ:MIRM) Q2 2021 earnings call, held 2021-08-05. Watch the replay and read the transcript on 6ix.

Thu, August 5, 2021 at 4:30 AMendedReplay
Mirum Pharmaceuticals (NASDAQ:MIRM) Q2 2021 Earnings Call
Company
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Period
Q2 2021 earnings call
Date
Thu, Aug 5, 2021, 4:30 AM ET
Replay
Watch the replay on this page · 39 min
Results news release
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update · Thu, Aug 5, 2021

On 6ix: 6ix.com/event/mirum-pharmaceuticals-inc-mirm-q2-2021-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Hello everyone and welcome to the Mirren Pharmaceuticals, Inc. second quarter 2021 business update. My name is Simona and I will be your coordinator today. You will have the opportunity to ask a question after the presentation. If you would like to ask a question, you may do so by pressing star followed by one on your telephone keypad. I will now hand you over to your host, Ian Clements, Chief Financial Officer, to begin. Ian, please go ahead.

0:25 Thanks, Simone, and good afternoon, everyone. I'd like to welcome you to Mirren Pharmaceuticals' second quarter 2021 conference call. I'm joined today by our president and CEO, Chris Peetz, and our chief operating officer, Peter Radovich. Earlier this afternoon, Mirren issued a news release announcing the company's results for the quarter ended June 30, 2021. Copies of this news release and SEC filings can be found in the investor section of our website. Before we begin, I'd like to remind you that during the course of this conference call, we will be making certain forward-looking statements about MIRM, and that program is based on management's current expectations, including statements regarding MIRM's business plans, development programs, strategies, prospects, commercialization and market opportunities, financial forecasts and guidance, anticipated FDA interactions or announcements, and certain other business methods.

1:23 These statements are subject to numerous risks and uncertainties, and actual results could differ materially from the results anticipated by these statements. Investors should read the risk factors set forth in Miriam's 10-Q for the quarter ended June 30, 2021, and any subsequent reports filed with the SEC. All statements are made as of today, August 5, 2021, and are based on information currently available to us, and Miriam does not undertake any obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. With that said, I'd like to turn the call over to Chris Peetz. Chris?

2:05 Thanks, Ian. Good morning, or good afternoon, to everyone. Thanks for bearing with our technical difficulties getting kicked off. With our PDUFA date of September 29th for Mirelixibet, our focus is squarely on the realization of this upcoming potential launch. Algeol syndrome is the leading genetic cause of pediatric liver transplant, many of these driven by the severe pruritus and symptomatic burden of disease. These patients are waiting for new treatment options. We estimate that algeol syndrome alone may be a more than $500 million opportunity for Mirelixibet, and we are launch ready and now have assembled a team and financial resources for successful commercialization, all while expanding our pipeline of potentially registrational studies in other rare liver diseases.

2:54 Miriam is focused on advancing life-changing medicines. Today, we will recap and provide context around some of our most exciting recent steps as we continue to realize our vision of being the leading rare liver disease company. I will cover our regulatory and pipeline updates, as well as the additional value we continue to build within NIRM's clinical programs. Peter will share updates on commercialization, and Ian will summarize our financial highlights. With our Purdue-to-date Tremorilixibet and cholestatic pruritus associated with Allergy Syndrome next month, our team is ready to launch upon a potential approval. Our regulatory review remains on track. and we've been able to accommodate all inspections to date and the FDA has continued to indicate no plans for an advisory committee.

3:45 If approved in the U.S., Merilixibat would serve as the first treatment approved for patients with Algeo Syndrome. In the ICONIC study, which served as a pivotal study, highly significant improvements in pruritus were observed with more than 80% of participants achieving a one-point reduction in itch score. We have six years of follow-up data and see durable responses in trial participants across the extensions of all three randomized studies of Mariluzabat and Allergy Syndrome. An approval and subsequent commercial launch would mark an important milestone for us at NIRM, and more critically, an important milestone for patients living with this terrible disease. We remain committed to further building on the body of evidence supporting Mariluzabat's potential in Allergy Syndrome.

4:34 In June, we presented an integrated safety analysis of Merilixibab in patients with Allergil Syndrome at the EZL Congress. These data resulted from five years of Merilixibab treatment across 86 patients and continues to reinforce our understanding of the drug safety and tolerability profile in patients with Allergil Syndrome. Mariluxabat was well tolerated in these patients for more than five years, with the most common treatment emerging adverse events reported being diarrhea and abdominal pain. An iconic diarrhea incidence was at similar rates between Mariluxabat and placebo during the placebo-controlled portion of the study. Also in June, we presented Mariluxabat transplant-free survival data for progressive familial intraparticulospaces type 2, or PfeC2, at the World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting.

5:29 As detailed in our presentation, Merilithabat-treated patients who achieved 75% serum bile acid reductions were shown to have 100% five-year native liver survival. These PFIC-2 data are under review with the European Medicines Agency. Building on that, our Phase III March PFIC study continues to advance well. with greater than 65 patients randomized with PFIC subtypes 1, 2, 3, and 4 across two cohorts. As a reminder, March PFIC evaluates a higher dose of Mariluxibet and has been shown to drive greater bile acid clearing. We plan to extend enrollment and expect top-line data in the second quarter of 2022. Further broadening our efforts in pediatric liver disease, our Phase IIb EMBARQ study Evaluating Muralixibet and Biliary Atresia is progressing nicely as well, and we anticipate top-line data in 2023. In adult liver disease, we are excited about advancing our clinical programs for Gullixibet, which we believe is another potentially transformative treatment for several cholestatic liver diseases.

6:40 Earlier this year, we launched our Phase IIb VISTA study for adults with primary sclerosing cholangitis, and a Phase 2b OHANA study that will evaluate volixibat in intra-hepatical spaces of pregnancy. A Phase 2b study in primary biliary cholangitis is targeted for later this year. We've incorporated regulatory feedback into the design of these volixibat studies, all of which are potentially registrational. We expect interim analyses for the VISTAs and OHANA studies to occur next year. And before heading off to Peter to discuss launch readiness, I want to touch on Mirim's commitment to ensuring broad, global access to Mariluxabat for Allergy Syndrome patients. To facilitate the international reach of Mariluxabat, we recently entered into an exclusive licensing agreement with GC Pharma to develop and commercialize Mariluxabat in South Korea. This builds on our partnership with Cambridge Pharmaceuticals in Greater China, which we announced in April. Both GC Pharma and Cambridge are leaders in rare disease and share our passion to advance life-changing medicines, and we'll pursue expedited approval pathways for Merilixivet for Allergy Syndrome based on our U.S. filing package.

7:55 We see the high interest level of our partners as testament to the potential of Merilixivet for pediatric cholestasis patients. On that note, I'll turn it over to Peter, who will provide an overview of our launch readiness activities. Peter?

8:13 Thanks, Chris. With our PDUPA date of September 29th, just over a month away, our team is ready to deliver Meritibat to the Allergy Health Syndrome community should it receive FDA approval. In the last quarter, we have made significant progress in our pre-commercialization efforts. Our strategy has centered on three areas, disease awareness and patient finding, patient services, and market access. Starting with disease awareness and patient finding, Our field sales team is hired, fully trained, and has been in the field for more than two months. We have connected with all of our key 125 accounts, including in-depth personalized discussions with the majority. The team is providing disease awareness education on algea syndrome, including recognizing the impact and severity of pruritus.

9:06 We are gaining valuable account profiling insights from these discussions, including working with healthcare professionals to identify patients with algea syndrome. Additionally, as part of our patient identification efforts, NIRIN participates in an industry collaboration genetic testing program, which provides free genetic testing and identifies mutations in JAG1 and NOTCH2, which cause algea syndrome. Together with what we've learned in our field discussions, as well as the genetic testing program, our clinical research and expanded access programs also support our estimates that there are 2,000 to 2,500 children with Algeo Syndrome in the United States.

9:51 We continue to work with healthcare professionals to identify patients as we approach the potential launch of Merrillix VET. Turning to patient services, Merim Access Plus, or MAP, which is Merim's program to provide end-to-end support for Allergy Ill Syndrome patients and caregivers initiating Maralizabat upon potential approval, is ready to go. The MAP team has been staffed and trained. Full operational readiness will occur in the coming days in order to start preparing EAP patients to transition to commercial product upon a potential FDA approval. Finally, regarding market access, the payer team has been very busy.

10:36 We have conducted 53 engagements within our top accounts. The team has been educating Medicaid and commercial payers on the burden of Allergy Health Syndrome in order to prepare them to conduct timely and evidence-based reviews and ultimately access decisions upon potential approval. We've invested early on this front. The burden of this disease is hard to overstate, and the broader community is learning about this dynamic, that cholestatic pruritus is a leading indication for transplant and surgery in algea syndrome. Overall, payers have recognized the devastating impact of algea syndrome and the high clinical impact of maralixibab. We remain passionate about and confident in maralixibab and the profound impact we expect it to have on the algea syndrome community.

11:26 I'm thrilled about our progress today and look forward to sharing more about our ongoing efforts with an update after our PDUFA date this month. I will now turn the call over to Ian to share financials. Ian?

11:44 Thanks, Peter. A fulsome look at our quarterly financials is available in the press release distributed earlier this afternoon and in the Form 10-Q. You can find both on the Investors section of our corporate website at NIRMpharma.com. I'll provide an overview of what we believe to be the highlights from the second quarter of 2021, all of which position us well to support the launch of MariluxABAT in two geographies and advance our development pipeline for both MariluxABAT and VeluxABAT in their respective indications. Miriam remains well-funded. At the close of the second quarter, ended June 30, 2021, we had cash, cash equivalents, and investments of $238.8 million. And also, as a reminder, we have access of up to a further $85 million from Oberlin Capital.

12:34 This figure comprises $35 million upon approval of our NDA of myelixibat for pruritus in Allergy Syndrome, and a further $50 million for mutually agreed-upon in-licensing or acquisition opportunities. Additionally, we anticipate receiving a Priority Review Voucher, or PRV, in connection with our expected FDA approval at Maralex later this year that may provide a further source of funds. With respect to operating expenses, for the quarter ended June 30, 2021, our G&A expenses were $13.4 million. This amount reflects increased activity around launch readiness, including market research, disease state awareness activities, and increased personnel costs to support our planned launches.

13:24 Second, R&D expenses were $35 million compared to $18.6 million for the second quarter of 2020. The increase here was primarily driven by an upfront payment and funding associated with the Vivette gene therapy programs and with the costs associated with initiation of our Velixibab clinical studies. As Chris alluded to, part of our strategy at NIRM is to accelerate commercial launch and patient access globally through partnerships outside of our core US and EU territories. On April the 29th, 2021, we announced a licensing agreement with Cambridge Pharmaceuticals. Under the terms of this agreement, in exchange for an $11 million upfront payment, R&D funding, and up to a further $109 million for future regulatory and commercial milestones, Cambridge has obtained the exclusive rights to develop and commercialize Maralexabat within the Greater China regions for allergy or syndrome, PFIC, and bariatric seizure. We can expect double-digit tiered royalties based on future product net sales.

14:33 Additionally, subsequent to the quarter end, we entered into an exclusive licensing agreement with GC Pharma, And in terms of this agreement, GC Pharma has obtained the exclusive right to develop and commercialize Maralixabat within South Korea for Allergy Ill Syndrome, PFIC, and biliary atresia. We received a $5 million upfront payment and are entitled to further research and development funding and up to $23 million for the achievement of future regulatory and commercial Maralixabat milestones with double-digit tiered royalties based on product net sales. So as a result of strategic investments, an experienced team, and focused rare disease business model, we continue to have a robust balance sheet. With access to approximately $400 million in capital comprised of our cash position, the potential PRV monetization, and strategic partnerships, we expect to be able to sustain our operations for the next three years.

15:32 With that, I'll turn the call over to Chris for final comments. Chris?

15:37 Thanks, Sam. And thanks again to everyone who joined the call today. To close, Merrim continues to pave the way for the treatment of rare liver diseases. With the potential FDA approval for the first-ever medicine to cholestatic, pruritus, and allogeal syndrome, and our other clinical programs continuing to progress across a wide range of indications, we are well on our way to realizing the company's vision set forth two and a half years ago. To briefly recap our upcoming milestones, Our producer date is September 29th for Merilixibat for the treatment of cholestatic pruritus in patients with Allergy Syndrome. Upon potential approval, U.S. commercial launch will follow, and we estimate this to be a greater than $500 million opportunity. We have upcoming key data updates on the pediatric program with long-term liver-related outcomes analyses in Merilixibat-treated patients with Allergy Syndrome, targeting upcoming medical congresses for presentation, and top-line data of the March PFIC Phase III study of Merrillix-Batton PFIC in Q2 next year.

16:42 Potential international regulatory events ahead include the PFIC II NAA under review with EMA, subsequent filing for Al-Jil syndrome in Europe and potential for partner market approvals. Finally, our Registrational Program for Velixibat in Adult Cholestasis has taken shape, with interim analyses next year of the OHANA and VISTA studies in intrapatic cholestasis of pregnancy and primary sclerosing cholangitis. Lastly, initiation of the Phase IIb study in primary biliary cholangitis is still to come this year. We take pride in the meaningful scientific advances we have achieved so far. and our ongoing engagements with the rare liver disease patient community as we continue to execute and maintain a strong cash position.

17:30 We are confident in our ability to achieve the milestones we have set for Miriam and look forward to the potentially transformative impact Mary Elizabeth and Elizabeth could have on the lives of patients and their families. Thank you again for joining us. Operator, would you please now open the line for questions? Thank you, Chris. If you would like to ask a question, please press star followed by 1 on your telephone keypad now. If you change your mind, please press star followed by 2 to cancel your request. When preparing to ask your question, please ensure that your phone is unmuted locally. Our first question is from Mani Foroohar of SBB Lyric. Mani, your line is open. Please proceed with your question. Good afternoon. This is Greco on for Mani.

18:15 Thanks so much for taking my questions. I'm hoping you could bridge us through the early period in the Merrill-Luxembourg launch and Alakil. How should we think about timing of Medicaid reimbursement in terms of translating new prescription patient volumes into revenue for Medicaid patients for the upcoming launch?

18:40 I agree. Thank you for the question. Actually, I'll turn to Peter to talk through some of our efforts on that front and how to think about The months and quarters ahead.

18:50 Sure. Thanks for the question. and, you know, as we mentioned in our comments, our payer team is out now actively engaging with these accounts with the goal of kind of facilitating, you know, timely reviews upon a potential approval. You referenced the Medicaid system specifically. So, you know, manufacturers do need to contract with HHS for a rebate agreement. And if the timing for, you know, the Merrill Expat approval comes around up to this date, We'd expect access and availability to participate in the Medicaid program to open up early next year. And then I think the other point is on the commercial side, there's a lot of different plans out there, kind of a heterogeneity of practices around coverage decisions and how those are made and when those are made, including some that will have NVC blocks for any new medicine, any new specialty medicine off the bat. So I think the headline point is Medicaid will be probably a quarter delay.

19:50 and on the commercial side, it'll be heterogeneous with variable delays. Got it. Great. Appreciate the comments and thanks again for taking my question. I'll have that in the queue.

20:04 Thanks. Our next question is from Yasmeen Rahimi of Piper Sandler. Yasmeen, your line is open. Please go ahead.

20:14 Hi, team. Thank you so much for taking my questions. A number of them for you. Maybe the first place to start would be, how should we be thinking about what are key tech items for payers? We recently received some pricing details for another IVAT inhibitor approved for the treatment of PFIC. So do you think that pricing could be competitive between PFIC and AllerGeal? And then the second question is, what is the likelihood of potentially being able to have the six-year event-free survival analysis to be part of the label? And then I have one more follow-up.

21:00 Great. Thanks for the question. I'll touch on a couple of those points and then turn over to Peter to talk a little bit about what we do on the patient side to support access. From a starting point, allogel syndrome and PFIC are different indications. As we think about our pricing decision and the value that we see in our long-term data and the profound impact that Merrill looks at that in our pivotal study, that's how we're going to be basing some of our pricing decisions as we head into them. on that long-term data, on being able to look at long-term outcomes from an event-free survival analysis. And Algeel syndrome, that's work we're doing now, so it has not been part of the FDA conversation.

21:49 We wouldn't expect that to be part of the label. Our conversation with FDA is based on what we've set out from the outset in a pre-IND discussion with them, which is around the impact on pruritus in these patients where pruritus drives many of the liver transplant decisions. So that's what we expect to be in an eventual potential label. Maybe I'll turn it over to Peter to give a little color on what this looks like on the patient side, some of the things that we can do to support access and patient navigation efforts.

22:27 Thanks, Chris. Yeah, our Miriam Access Plus or MAP program will really be the central nervous system for this, both for the patient and caregiver navigating logistical or financial out-of-pocket kind of implications, depending on that particular patient's insurance status, as well as collaborating with health care professionals. I think the expectation that we largely have and we see with other specialty medicines is payer practices, ultimately PA to label kind of an approach, a prior authorization to label. So really evidence-based approaches to access to new medicines.

23:09 Thank you. Maybe two quick follow-ups. Can you maybe highlight, given the work that you guys have done with 125 accounts, what percentage of the addressable market out of the 2,000 to 2,500 patients in the US could become eligible right away within the first year of launch? And then the second question I have is on the timing of March PFIG. Are you able to comment on What percentage of total enrollment has been achieved at this point? And thank you so much for taking on my long question.

23:53 No problem. Thanks for the question, as always. I'll start with the finish and then hand it back over to Peter to talk about some of the account dynamics and patient finding. But on March PCIC, So as said in the prepared remarks, we're over 65 patients randomized. That study can go up to 90, but is not needed to go up to 90. So we are looking at the balance across the PFIC subtypes, trying to hit a target distribution that we're getting quite close to. It's kind of some of the color I can give on the dynamic there. So over 65 patients. and getting close to completion. Peter, do you want to speak to the account and patient funding dynamic?

24:44 Sure, sure. Happy to provide a little bit of color there. So as I mentioned, our field team has been out there profiling those 125 accounts for over two months now and certainly finding patients and ultimately we're kind of confident in the estimates we put out there in terms of total number of patients. based on those interactions among other data points. I think your specific question was about how many of them would be kind of initial candidates. I think what we see, and this is probably not uncommon in any genetic disease, is phenotypic variability in the presentation and probably approximately half of the patients with algea syndrome have pretty severe disease and are really kind of refractory to the available off-label therapies that are out there today.

25:36 So I would kind of think of that as an initial kind of place, probably a logical place to start, I think, in terms of utilization. But ultimately, building out over time, you know, we're confident that Merrill looks back to address the full population. Thank you. Thank you, Yasmeen. Our next question is from Ed Arse of HC Wainwright. Ed, your line is open. Please proceed with your question. Hey, good afternoon, everyone. This is Thomas here asking a couple of questions for Ed. So first, regarding P52 in Europe, you mentioned that an area decision is anticipated there early next year. Can you talk briefly about the progress of commercial prep there?

26:33 Any specific countries or areas of focus that you have in mind for now?

26:41 Thanks so much for the question. Actually, I'll turn to Peter to talk about that and give a little color on how we think about it globally about the various markets and what we're doing to get ready for approvals.

26:54 Thanks for the question. We have built an international team that covers Europe and really all F2S territories. Within Europe, we're planning direct commercialization in kind of Central and Western Europe as really our footprint. and really focused on the big five initially and have built out a commercial and medical affairs team among others, the GMA support team there and really focused on launch prep key stakeholder engagement in that region. And then as Chris alluded to, we're also very active looking in markets with partners. I think we talked about in our prepared remarks South Korea and China where there's an opportunity were expedited regulatory pathways based on the US potential approval, as well as other geographies where it's possible to reach those markets in a relatively attractive timeline and also favorable market access. So Europe is certainly part of the international expansion plan, but we think there's a lot of opportunity even outside of Europe.

28:07 Thanks for the additional details. I'm perhaps still on PFIG for the Phase 3 March study data that's coming in the second quarter next year. Do you guys have any progress with the FDA specifically regarding what specifically they're looking for for PFIG approval in the U.S., or are we holding patent until we see the data?

28:41 Thanks for the question. So the March PFIX study was extensively discussed with FDA. So we've worked everything into that study to address what they're looking for. So, of course, we have to get to the results, but we feel confident that the dose of Mariluzabat in that study, we should see improvements on the activity levels that we saw in the Phase II indigo study. And looking forward to that readout in the second quarter. That sounds good. Perhaps one last question, this one for Ian. We went over major components of the U.S. launch perhaps for angiosyndrome.

29:28 Can you tell us really rough ballpark costs of each major component, so accounts and marketing and the patient access programs?

29:42 Yeah, thanks, Thomas. We haven't given specific kind of guidance around the kind of breakdown, but as you think about the The numbers of people and activities involved over the whole of our operating expenses, it's a fairly small number. Considering, if you think about Salesforce, for example, we've got 10 reps, customer team managers, MSL teams, about five people across the U.S. So a very compact and efficient model in terms of the commercialization stand from that perspective. Okay, that sounds good. Thanks again for taking our questions, and we look forward to the date in September.

30:31 Thanks for your questions. Thanks, Thomas. Our next question is from Steven Seedhouse of Raymond James. Steven, your line is open. Please go ahead. Hi, guys. This is Ryan Deshman. I'm for Steven Seedhouse. I wanted to ask, is the decision to submit the MAA for ALGS based only on the iconic six-year event-free survival data, or is there new additional long-term SBA paritis data in there?

31:03 Thanks for the question. So the MAA package that we're working towards for algeol syndrome does include an expanded data set. And so going back to some of the early conversations with EMA, about allogeal syndrome, and about PFIC as well, frankly, within these programs, is they had asked for incorporating looking at long-term outcomes in any submission. And so what we have been looking at with the allogeal syndrome package is in addition to ICONIC, which serves as a pivotal study in how we think about Europe, similar to the way it is in the U.S., We are looking at supportive analyses on long-term event-free survival. We also have a collaboration with the Natural History Effort looking at outcomes in the pooled Allergy Syndrome studies, so the three randomized Phase II studies and the open-ended follow-up that encompassed 86 children in total and the six years of follow-up.

32:11 Looking at that cohort of patients against a Natural History control group, and evaluating events through survival. That's work that's ongoing and will be part of the European package. Okay, that's helpful. And then I also wanted to ask, has the Phase IIb Embark study for biliary atresia activated sites in China via the Cambridge collaboration? And if so, how have patients started enrolling in China?

32:42 That's still to come. So we're active in site startup, but they're not open quite yet. Similar, we'll also look at Korea for sites working with GC Pharma. Okay. And then finally, in terms of future market share in China, how different would you anticipate market penetration to be across Allogeo, PFIC, and Billiard, Atresia versus in the U.S. market?

33:13 Thanks for the question. It's hard to really characterize that without kind of bringing Cambridge into the conversation, frankly, because there's some country-specific launch dynamics that as they get kicked off, I don't want to get ahead of speaking for them while they work on their launch plans and sequencing the indications. Okay. Thank you very much, Chris. Appreciate it.

33:44 Thanks for the question. Our next question comes from Brian Scorney of Baird Capital. Brian, your line is open. Please go ahead. Hi, this is Luke on for Brian. I was hoping to get a little more color on the Blixabat readouts expected next year. Can you talk a little more about the pace of enrollment and what you're thinking for the advocacy bar in those studies?

34:12 Yeah, absolutely. Thanks for the question. And so the two studies that we expect interims for next year are the OHANA study in colostasis of pregnancy and the VISTA study in PSC. These are both adaptive design Phase IIb studies. So in the first portion of each of these, they're looking at both 80 and 20 milligrams BID against placebo. So that's one of the first focuses of the interim analyses in each of these is to look at dose selection and to be able to consolidate those. So we'll be looking at comparative efficacy and serum bile acid movements between the two dose levels of Velixibat versus placebo as we make that dose decision.

35:00 And for the ICP study for Ohana, there's a unique feature to that study design that's worth mentioning. In addition to the formal blinded placebo-controlled portion of the study, there is an open label cohort of milder ICP patients. And that will give us our first interim from that study and get an early sense of activity level on serum bile acids and itch, what will be the couple of things to look at in that open label data. So really, we've designed these programs to be adaptive in a very strategic way so that we can have these roll into potentially registrational portions of the study after these interim time points.

35:51 So the interim analyses will guide that dose selection and sizing of the second portion of the studies. Great. Thank you.

36:05 Thanks for the question. As a reminder, should you wish to ask any further questions, please press star followed by one on your telephone keypad now. Our next question is from Etzer Daruth of Guggenheim Partners. Etzer, your line is open. Please proceed.

36:23 Great. Thanks for taking questions. Just a couple for me. Firstly, just wanted to maybe get your comments on any meaningful takeaways. from the competitor PFIC label as you sort of think about sort of post-March PFIC next year as it pertains to conversations with regulators. And secondly, sort of understand that the biliary atresia, the underlying cause of that disease is not well understood, but just wondered Your thoughts around sort of how de-risking ALGS, PFIC data sets in general could be as we kind of think about the biliary atresia readout in 2023. Thanks.

37:06 Yeah, thanks for the question. First, comment on the recent approval on PFIC. It's just great to see, right, to see a product approved in this really terrible indication and I think from a high level, what we saw there was really in line with expectations based on what we have learned from FDA's viewpoints on looking at pruritus as an approval endpoint in a setting like this, how it all ties into the transplant dynamic, and it's just a terrible component of this disease. So we see that as a great progress point for the space and how we think about our program as well. And moving to the biliary atresia point, that is a very different disease than Allergy syndrome and PFIC because of not only the heterogeneity, but also just the physical biology in a post-CASAI setting is different. It's a different disease, which is why we're approaching it in a different way with the EMBARQ study, looking at six-month bilirubin serum bile acids Those two serum markers being the most looked at and predictive prognostic markers in looking at transplant-free survival in some of the recent analyses that have been presented at scientific congresses. So looking to get a read in a relatively

38:37 quick timeframe on what the potential impact of Merilixabat is in these quite sick children.

38:49 Thank you. Thank you, Etta. We currently have no further questions, so I will hand you back over to Chris.

39:01 Great. Thank you, and thanks for joining the call today and for your interest in Neuron. We're excited about the events ahead of us. Patients suffering from allogeal syndrome are waiting for new treatment options, and we look forward to providing an update after the upcoming producer date. Thank you so much. Thank you all for joining. Have a great rest of your day. You may now disconnect your line.

Follow Mirum Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Ian Clements

Chief Financial Officer

Chris Peetz

President and Chief Executive Officer

Peter Radovich

Chief Operating Officer

Yasmeen Rahimi

Analyst, Piper Sandler

Etzer Daruth

Analyst, Guggenheim Partners

More from Mirum Pharmaceuticals, Inc.